


CARE-MG: MGFA's Registry to Track the Impact of COVID-19 on Myasthenia Patients

COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG)

CARE-MG, a **physician-reported** registry, is a joint effort of the International MG/COVID-19 Working Group and neurologists from across the globe to capture outcomes of people with myasthenia gravis who have developed COVID-19 infections.

Formally launched on April 9, 2020, this robust international effort – with patient participation from around the world - is critical to our collective success in answering these fundamental questions:

- Do MG patients face special risks after contracting COVID-19?
- Do baseline COVID-19 and MG therapies impact risk to patients?



Together, the two working groups along with several independent experts have designed and launched this international registry. We are counting on international physician participation and collaboration, and hope to capture the majority of COVID-19 cases in people with MG. We will rapidly define the impact of COVID-19 on patients with MG and how factors such as age, comorbidities, and treatments are associated with COVID-19 outcomes.

The registry is designed to capture outcomes in all types of myasthenia gravis (AChR, MuSK, LRP4, Seronegative) irrespective of current treatment status who have confirmed or suspected COVID-19 infection. It also includes MG patient data from 18+ countries.

Key Definitions:

- Laboratory Confirmed COVID-19 - Positive viral RNA tests or positive serology for SARS-CoV-2.
- Suspected COVID-19 but not confirmed - Fever with Dry cough, +/- anorexia, myalgias, dyspnea, anosmia/ageusia, potential exposure, Chest imaging suggestive of COVID.
- Myasthenia Gravis: As defined by treating physician based on antibody status and if seronegative (based on standard testing such as repetitive testing, single fiber EMG, response to acetylcholine esterase inhibitors).

Cases can be reported by physicians two ways:

- To report a case directly through the EDC (REDCap) system, <https://redcap.duke.edu/redcap/surveys/?s=H4EKCWLFKR>
- To report a case using the paper case report form (CRF), please download the paper form from this URL: myasthenia.org/CARE-MG-CRF and submit to Dr. Srikanth Muppidi via email to: COVID-19MGstudy@duke.edu

We ask you to register any appropriate patient, regardless of severity (including asymptomatic patients detected through screening). Please report only after a minimum of 7 days and sufficient time has passed to observe the disease course through resolution of acute illness or death. Reporting a case to this database should take approximately 10 minutes. Necessary permission to collect these data from university institutional review board (IRB) has been obtained.

To Learn more about the CARE-MG Registry and read about published data, visit: myasthenia.org/CARE-MG